Goal: For women diagnosed with preeclampsia between 23 and 30 weeks:
â€¢ Safely prolong pregnancy by delaying delivery
â€¢ Improve outcomes of baby
Who can participate?
â€¢ At least 16 years of age or older
â€¢ Singleton pregnancy
â€¢ 23 to 30 weeks pregnant with a recent diagnosis of preeclampsia or superimposed preeclampsia
â€¢ Requiring monitoring in a hospital setting
The PRESERVE-1 study will include 120 women at over 20 locations in North America: https://www.clinicaltrials.gov/ct2/show ... ocs=Y#locn.
New Haven, CT
New Orleans, LA
St. Louis, MO
New York, NY
Salt Lake City, UT
PRESERVE-1 is a Phase 3 clinical study for women who are diagnosed with preeclampsia between 23-30 weeks of their pregnancy. This study will assess if antithrombin (Recombinant), a man-made version of a naturally occurring blood protein, can increase the time that your baby stays in the womb, decrease the problems that you may experience or improve the health and well-being of your baby.
What to Expect:
Participation in this study will involve gathering your medical history, physical exams, blood and urine collection, taking the study medication, and monitoring for side effects under observation by a physician. Some participants will receive the medication and some participants will receive a placebo, which is a saline solution without active ingredients. Your baby will also be followed after delivery.
1 post • Page 1 of 1
Users browsing this forum: No registered users and 1 guest